Service Line:+1-315-239-3085
Address:FL-4, Building A5, International Enterprise Community, Tianjin, China
Email:info@kmdbioscience.com
Catalog Number | YR1160 |
---|---|
Product Name | Anti-Human CD152 Recombinant Antibody(Tremelimumab) |
Molecular Name | Tremelimumab |
Alias | Anti-CD152 Recombinant Antibody, Research Grade Tremelimumab |
CAS Number | 745013-59-6 |
Target | CD152[Homo sapiens] |
Isotype | IgG2 Kappa |
Clonity | Monoclonal |
Source | CHO Cells |
Size | 1mg, 5mg |
Concentration | 1mg/ml |
Purity | >95% as determined by SDS-PAGE |
Applications | IF, IP, Neut, FuncS, ELISA |
Buffer | PBS, pH7.5 |
Background | Tremelimumab (formerly ticilimumab, CP-675, 206) is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker. Previously in development by Pfizer, it is now in investigation by MedImmune, a wholly owned subsidiary of AstraZeneca. It has been undergoing human trials for the treatment of various cancers but has not attained approval for any. |
Storage | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
Note | This product is for research use only. |